Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin

NCT00234065 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00234065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00234065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2003
Completion date
December 31, 2008
Enrollment
2,800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral infarction